| 翻訳と辞書 |
| Oncolytics Biotech ： ウィキペディア英語版 |
Oncolytics Biotech
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that focuses on the development of pharmaceutical products for the treatment of human cancers. The product Reolysin harnesses the oncolytic capabilities of naturally-occurring reovirus (Respiratory Enteric Orphan virus), which has been shown to replicate specifically in cells with an activated Ras pathway. Ras pathway mutations are found in approximately two thirds of all tumours, including most metastatic disease, which makes Reolysin a potential therapeutic for cancer.
==History==
Oncolytics Biotech Inc. was founded in Calgary in 1998 in response to discoveries made on the oncolytic potential of reovirus made at the University of Calgary during the 1990s. From 1999 to 2000 the company transitioned from private to public ownership. In June 2000, it began trading on the Toronto Stock Exchange (TSE) and began trading on the NASDAQ in 2001.
Since its inception, Oncolytics Biotech Inc. has worked to take Reolysin, its proprietary formulation of human reovirus, through the development and regulatory requirements necessary to develop it as a potential cancer therapeutic. In 2000, Oncolytics Biotech Inc. received permission to conduct its first phase I clinical trial, which was designed to test the safety of Reolysin in human patients. The positive results of this first study led to the rapid and continuous expansion of Oncolytics’ clinical trial program, with phase II studies beginning in Canada in 2001, U.S. and subsequent cross-border studies beginning in 2002, and enrollment in a multi-site phase III trial beginning in 2010.
The company was issued its first Canadian patent in August 2000, and currently holds more than 200 patents worldwide, including 38 U.S. and 11 Canadian patents.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Oncolytics Biotech」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|